Heidelberg Pharma AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
February 05, 2018 at 06:40 am EST
Share
DGAP Voting Rights Announcement: Heidelberg Pharma AG
Heidelberg Pharma AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
05.02.2018 / 12:37
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
Heidelberg Pharma AG
Schriesheimer Str. 101
68526 Ladenburg
Germany
2. Reason for notification
X
Acquisition/disposal of shares with voting rights
Acquisition/disposal of instruments
Change of breakdown of voting rights
Other reason:
3. Details of person subject to the notification obligation
Name:
City and country of registered office:
Mr Dietmar Hopp, Date of birth: 26 Apr 1940
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
5. Date on which threshold was crossed or reached:
19 Jan 2018
6. Total positions
% of voting rights attached to shares (total of 7.a.)
% of voting rights through instruments (total of 7.b.1 + 7.b.2)
total of both in % (7.a. + 7.b.)
total number of voting rights of issuer
Resulting situation
75.16 %
0.00 %
75.16 %
28095419
Previous notification
70.26 %
0.00 %
70.26 %
/
7. Notified details of the resulting situation a. Voting rights attached to shares (Sec.s 33, 34 WpHG)
ISIN
absolute
in %
direct (Sec. 33 WpHG)
indirect (Sec. 34 WpHG)
direct (Sec. 33 WpHG)
indirect (Sec. 34 WpHG)
DE000A11QVV0
171538
20943725
0.61 %
74.54 %
Total
21115263
75.16 %
b.1. Instruments according to Sec. 38 para. 1 No. 1 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Voting rights absolute
Voting rights in %
%
Total
%
b.2. Instruments according to Sec. 38 para. 1 No. 2 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Cash or physical settlement
Voting rights absolute
Voting rights in %
%
Total
%
8. Information in relation to the person subject to the notification obligation
Person subject to the notification obligation is not controlled and does itself not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).
X
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:
Name
% of voting rights (if at least held 3% or more)
% of voting rights through instruments (if at least held 5% or more)
Total of both (if at least held 5% or more)
Zurechnungsstrang 1 - attribution of shares 1
%
%
%
Herr Dietmar Hopp
- %
- %
- %
DH-Holding GmbH & Co. KG
- %
- %
- %
DH-Holding Verwaltungs GmbH
3.33 %
- %
- %
Zurechnungsstrang 2 -attribution of shares 2
%
%
%
Herr Dietmar Hopp
- %
- %
- %
Hopp LT Vermögensverwaltung GmbH
- %
- %
- %
DH-Capital GmbH & Co. KG
- %
- %
- %
dievini Hopp BioTech holding GmbH & Co. KG
71.21 %
- %
71.21 %
Zurechnungsstrang 3 - attribution of shares 3
%
%
%
Herr Dietmar Hopp
- %
- %
- %
DH Verwaltungs GmbH
- %
- %
- %
DH-Capital GmbH & Co. KG
- %
- %
- %
dievini Hopp BioTech holding GmbH & Co. KG
71.21 %
- %
71.21 %
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
Date of general meeting:
Holding position after general meeting:
% (equals voting rights)
10. Other explanatory remarks:
05.02.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Companyâs pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.
Heidelberg Pharma AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution